Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Debiopharm Group, Biocartis sign investment agreement

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.

8 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

Gerresheimer AG sets up new sales office in Moscow

Gerresheimer AG has set up a sales office in Moscow. The new representation centre will intensify the Group's business in pharmaceutical primary packaging and drug-delivery systems. "This is a strategically important step to further develop the fast-growing pharma & healthcare markets of Russia and neighboring regions," says Gerresheimer CEO Dr. Axel Herberg.

7 Apr 2010

Officials of Kylin Therapeutics receive an issued patent from USPTO

Officials of Kylin Therapeutics Inc., a leading RNAi company, announced this week that they received an issued patent from the U.S. Patent and Trademark Office.

7 Apr 2010

BD Diagnostics adds Innova Preanalytical Automated Microbiology Specimen Processor to product portfolio

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today the expansion of its product portfolio with the addition of the BD Innova™ Preanalytical Automated Microbiology Specimen Processor, which is designed to help increase laboratory efficiency and automate the modern microbiology laboratory.

From BD (Becton, Dickinson and Company) 7 Apr 2010

Halozyme Therapeutics secures multiple commercial supply agreements for rHuPH20

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the execution of multiple commercial supply agreements with its existing manufacturing partners. Halozyme amended an existing commercial supply agreement with Avid Bioservices, Inc., entered into a new commercial supply agreement with Avid and entered into a new commercial supply agreement with Cook Pharmica LLC.

5 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

Scientific American features Echo Therapeutics' non-invasive, wireless Symphony tCGM System

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that its Symphony™ tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," by Larry Greenemeier.

3 Apr 2010

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

CPEX Pharmaceuticals Inc. today announced that its partner, Serenity Pharmaceuticals, has entered into a global agreement with Allergan, Inc. for the development and commercialization of Ser-120, a product candidate currently in Phase III clinical trials for the treatment of nocturia that utilizes CPEX's patented intranasal drug delivery technology.

2 Apr 2010

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.

2 Apr 2010

Protein vaccines for needle-free immunization through the skin

Most immunizations currently involve an injection in the arm. In the future, vaccination may be accomplished without the unpleasant jab of a needle: a team led by Victor C. Yang at the University of Michigan (USA) has developed a method by which vaccines can pass directly through the skin without a needle. As the researchers report in the journal Angewandte Chemie, merely linking a special short peptide molecule to the vaccine, which can then be administered in the form of a patch, will do the job.

1 Apr 2010

Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment

Cipher Pharmaceuticals Inc. today announced that it has reached the enrollment mid-point in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. To date, more than 400 patients have been enrolled. Achieving this milestone triggers a US$2.0 million milestone payment from Ranbaxy Pharmaceuticals Inc., Cipher's U.S. marketing and distribution partner.

1 Apr 2010

Soligenix's revenues for 2009 increase by 22%

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

1 Apr 2010

DSMB for DIGNITY trial recommends Celsion continue enrollment

Celsion Corporation announced today that after reviewing safety data from the 40mg/m2 cohort, the DIGNITY Study Drug Safety Monitoring Board (DSMB) has recommended that Celsion continue to enroll patients in the trial and that new patients be treated at a ThermoDox® dose of 50mg/m2.

31 Mar 2010

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

31 Mar 2010

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

ACCESS PHARMACEUTICALS, INC. signed a collaborative development agreement with bioRASI, LLC, a full-service global CRO specializing in the accelerated development of novel therapeutics, to facilitate clinical development for its Cobalamin™-based oral insulin and other Cobalamin-based products.

31 Mar 2010

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).

31 Mar 2010

Insight into scorpion venom may help understand diseases like pancreatitis

A Brazilian scorpion has provided researchers at North Carolina State University and East Carolina University insight into venom's effects on the ability of certain cells to release critical components. The findings may prove useful in understanding diseases like pancreatitis or in targeted drug delivery.

30 Mar 2010

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.

30 Mar 2010

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.

29 Mar 2010

Drug Delivery News and Research

Further Reading

Debiopharm Group, Biocartis sign investment agreement

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

Gerresheimer AG sets up new sales office in Moscow

Officials of Kylin Therapeutics receive an issued patent from USPTO

BD Diagnostics adds Innova Preanalytical Automated Microbiology Specimen Processor to product portfolio

Halozyme Therapeutics secures multiple commercial supply agreements for rHuPH20

Cancer research at Georgia Tech: Report

Scientific American features Echo Therapeutics' non-invasive, wireless Symphony tCGM System

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Protein vaccines for needle-free immunization through the skin

Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment

Soligenix's revenues for 2009 increase by 22%

DSMB for DIGNITY trial recommends Celsion continue enrollment

Depomed licensee submits DM-1796 NDA for management of PHN

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Insight into scorpion venom may help understand diseases like pancreatitis

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News